Dianthus Therapeutics (DNTH) Depreciation & Amortization (CF) (2017 - 2023)
Dianthus Therapeutics (DNTH) posted quarterly Depreciation & Amortization (CF) of $27000.0 for Q3 2025, up 8.0% year-over-year from $25000.0 in Q3 2024, and down 10.0% quarter-over-quarter from $30000.0 in Q2 2025.
Powered by 
Analysis
Dianthus Therapeutics (DNTH) Depreciation & Amortization (CF) (2017 - 2023) Analysis & Trends
Dianthus Therapeutics' Depreciation & Amortization (CF) history runs 9 years deep, the most recent figure standing at $27000.0 for Q3 2025.
- In Q3 2025, Depreciation & Amortization (CF) rose 8.0% year-over-year to $27000.0; the TTM figure through Dec 2025 stood at $84000.0 (down 12.5% YoY), while the FY2024 annual figure was $96000.0, up 43.28% from the prior year.
- Depreciation & Amortization (CF) for Q3 2025 stood at $27000.0, down from $30000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $535000.0 in Q4 2021, with the low at $19000.0 in Q3 2023.
- The 5-year median for Depreciation & Amortization (CF) is $225500.0 (2023), against an average of $254722.2.
- The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) sank 95.97% in 2023, then surged 31.58% in 2024.
- Dianthus Therapeutics' Depreciation & Amortization (CF) stood at $535000.0 in 2021, then decreased by 12.9% to $466000.0 in 2022, then plunged by 95.71% to $20000.0 in 2023, then increased by 30.0% to $26000.0 in 2024, then advanced by 3.85% to $27000.0 in 2025.
- Business Quant data shows DNTH's Depreciation & Amortization (CF) at $27000.0 in Q3 2025, $30000.0 in Q2 2025, and $27000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Dianthus Therapeutics | 4.09 Bn | 3.69 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | 421,000.00 |
| Dec 31, 2022 | 466,000.00 |
| Sep 30, 2022 | 471,000.00 |
| Jun 30, 2022 | 477,000.00 |
| Mar 31, 2022 | 511,000.00 |
| Dec 31, 2021 | 535,000.00 |
| Sep 30, 2021 | 532,000.00 |
| Jun 30, 2021 | 479,000.00 |
| Mar 31, 2021 | 474,000.00 |
| Dec 31, 2020 | 517,000.00 |
| Sep 30, 2020 | 495,000.00 |
| Jun 30, 2020 | 495,000.00 |
| Mar 31, 2020 | 493,000.00 |
| Dec 31, 2019 | 485,000.00 |
| Sep 30, 2019 | 483,000.00 |
| Jun 30, 2019 | 452,000.00 |
| Mar 31, 2019 | 423,000.00 |
| Dec 31, 2018 | 359,000.00 |
| Sep 30, 2018 | 209,000.00 |
| Jun 30, 2018 | 160,000.00 |